The rationale is presented for recommending vaccination in all infants and children 6 through 23 months of age, children 6 months through 18 years of age who are moderately or severely immunocompromised, and children 2 through 18 years of age in certain additional risk groups, including those at high risk of severe COVID-19.
Abstract
This technical report accompanies the American Academy of Pediatrics policy statement recommendations for COVID-19 vaccination during the 2026-2027 respiratory virus season. The rationale is presented for recommending vaccination in all infants and children 6 through 23 months of age, children 6 months through 18 years of age who are moderately or severely immunocompromised, and children 2 through 18 years of age in certain additional risk groups, including those at high risk of severe COVID-19, residents of long-term care facilities or other congregate settings, children who have never been vaccinated against COVID-19, and children whose household contacts are at high risk for severe COVID-19. The report synthesizes currently available evidence on SARS-CoV-2 epidemiology, disease burden, COVID-19 vaccine effectiveness, vaccine safety, and vaccine cost-effectiveness in pediatric populations. Additionally, the report provides an overview of available COVID-19 vaccine products, formulations, storage and handling considerations, and coadministration with other immunizations.
This policy statement updates the recommendations of the American Academy of Pediatrics (AAP) for the use of COVID-19 vaccines in the prevention of severe COVID-19 in children. A review of evidence supporting these recommendations is in the accompanying technical report (https://doi.org/10.1542/peds.2026-079046). These...
This technical report accompanies the American Academy of Pediatrics (AAP) policy statement (https://doi.org/10.1542/peds.2026-079047) and recommendations for respiratory syncytial virus (RSV) immunization during the 2026-2027 RSV season. The rationale is presented for recommending immunization of all infants younger t...
INTRODUCTION
Pharmacists' impact on adult immunization access is well-documented, but limited data exist supporting involvement in vaccination efforts for individuals under 18 years. This study examined trends in child and adolescent COVID-19 vaccinations delivered by pharmacists in North Carolina.
METHODS
COVID-19 V...
Carrie M. Blanchard, Jenny Myers, Anna Louise McNabb et al.· Vaccine· 0 citations
A review of evidence supports expanding the high-risk criteria for administration of RSV immunization in infants and children 8 through 19 months of age entering their second RSV season.
COVID-19 vaccination in pregnancy, with or without influenza vaccine coadministration, was safe and well-tolerated by survey respondents and no new or worsening health problems were reported after coadministration of COVID-19 and influenza vaccines during pregnancy.
Sophie Tran, E. McClymont, S. Blitz et al.· Vaccine· 0 citations